BUDGET IMPACT OF FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA AND NEOVASCULAR AGE RELATED DEGENERATION IN CANADA

被引：0
|
作者：
Buhrer, C. [1 ]
Diles, D. [2 ]
机构：
[1] F Hoffmann La Roche, Basel, Switzerland
[2] Hoffmann La Roche Ltd, Mississauga, ON, Canada
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE76
引用
收藏
页码：S73 / S73
页数：1
相关论文
共 50 条
  • [1] Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
    Desideri, Lorenzo Ferro
    Traverso, Carlo Enrico
    Nicolo, Massimo
    Munk, Marion R.
    [J]. PHARMACEUTICS, 2023, 15 (05)
  • [2] BUDGET IMPACT ANALYSIS OF FARICIMAB FOR TREATING PATIENTS WITH DIABETES MACULAR EDEMA OR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN PANAMA
    Hidalgo, J.
    Ordonez, J.
    Avlia, P.
    Munoz, J. M.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S93 - S93
  • [3] BUDGET IMPACT ANALYSIS OF FARICIMAB FOR TREATING PATIENTS WITH DIABETES MACULAR EDEMA OR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN GUATEMALA
    Hidalgo, J.
    Ordonez, J.
    Deutschmann, B.
    Arriola, A.
    Del Cid, J. M.
    Bustamante, W. Makepeace
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S159 - S159
  • [4] BUDGET IMPACT ANALYSIS OF FARICIMAB FOR TREATING PATIENTS WITH DIABETES MACULAR EDEMA OR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN COSTA RICA
    Hidalgo, J.
    Ordonez, J.
    Salas, M.
    Wu, L.
    Acevedo, R.
    Gutierrez, J. C.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S136 - S136
  • [5] Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
    Liberski, Slawomir
    Wichrowska, Malgorzata
    Kociecki, Jaroslaw
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (16)
  • [6] Faricimab (Vabysmo) for Age-Related Macular Degeneration and Diabetic Macular Edema
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2022, 64 (1646): : 45 - 46
  • [7] BUDGET IMPACT ANALYSIS OF FARICIMAB FOR TREATING PATIENTS WITH DIABETES MACULAR EDEMA OR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN EL SALVADOR, HONDURAS, AND DOMINICAN REPUBLIC
    Hidalgo, J.
    Santos, M.
    Deras, P.
    Castro, A.
    Flores, M.
    Roi, R.
    Gonzales, A.
    Mera, Asilis J.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S191 - S191
  • [8] Real-World Outcomes of Faricimab Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
    Quah, Nicole Q. X.
    Javed, Khawaja Muhammad Ammar Ali
    Arbi, Lamees
    Hanumunthadu, Daren
    [J]. CLINICAL OPHTHALMOLOGY, 2024, 18 : 1479 - 1490
  • [9] COST-EFFECTIVENESS OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CANADA
    Buhrer, C.
    Paulo, T.
    Diles, D.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S111 - S112
  • [10] Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes
    Agostini, Hansjuergen
    Abreu, Francis
    Baumal, Caroline R.
    Chang, Dolly S.
    Csaky, Karl G.
    Demetriades, Anna M.
    Kodjikian, Laurent
    Lim, Jennifer I.
    Margaron, Philippe
    Mones, Jordi M.
    Peto, Tunde
    Ricci, Federico
    Rueth, Matthias
    Singh, Rishi P.
    Stoilov, Ivaylo
    Swaminathan, Balakumar
    Willis, Jeffrey R.
    Westenskow, Peter D.
    [J]. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2024,
12345